Pharmaceutical Failure Investigations: 15 Practice Questions

Failure investigations are one of the most consistently cited areas in FDA pharmaceutical GMP inspections. The rules are not complicated, but applying them correctly under batch-release pressure, with incomplete information and competing organisational incentives, is where most manufacturers fall short. This practice test works through the scenarios where those judgements are most likely to go wrong.

Questions are drawn from FDA’s guidance on investigating out-of-specification (OOS) test results, 21 CFR 211.192, ICH Q10, and the pattern of FDA 483 observations and warning letters in pharmaceutical GMP enforcement. Reveal answers only after choosing your own.

Key principle: An investigation is not a paperwork exercise. It is an analytical process that must identify the root cause, extend to all potentially affected batches, and result in corrective actions that prevent recurrence. An investigation that concludes with no assignable cause when a true root cause exists is a compliance failure, not a neutral outcome.

Section 1: Fundamentals

Question 1 | Beginner

Under 21 CFR 211.192, when must a pharmaceutical manufacturer investigate a discrepancy or specification failure?

A) Only before the batch is distributed
B) Only if the batch has already been recalled
C) Whether or not the batch has been distributed
D) Only when requested by FDA

Question 2 | Beginner

Which phase of an OOS investigation specifically focuses on whether the OOS result was caused by a laboratory error?

A) Phase 2 investigation
B) Phase 1 laboratory investigation
C) CAPA implementation
D) Batch disposition review

Question 3 | Beginner

True or False: A passing retest result can be used to invalidate an original OOS result without a formal Phase 1 investigation.

A) True
B) False

Section 2: Compliance Requirements

Question 4 | Intermediate

Phase 1 of an OOS investigation is completed and no assignable laboratory cause is identified. What is the correct next step?

A) Reject and destroy the batch immediately
B) Open a Phase 2 production investigation examining manufacturing process, raw materials, equipment, and environment
C) Retest the sample three more times and average the results
D) Release the batch if all other batch record entries are satisfactory

Question 5 | Intermediate

Under 21 CFR 211.192, the investigation of a batch failure must extend to what?

A) Only the specific batch that failed
B) Other batches of the same drug product and other drug products that may have been associated with the failure
C) Only batches manufactured in the same calendar year
D) Only batches not yet distributed

Question 6 | Intermediate

What must be included in the documentation of a pharmaceutical batch failure investigation?

A) Only the test results and the final batch disposition decision
B) A clear statement of the reason for investigation, the scope, the root cause, the corrective action, and the effect on other batches and products
C) Only the CAPA form and the QA signature
D) A laboratory supervisor’s written opinion that the result was caused by analyst error

Section 3: Investigation Methodology

Question 7 | Intermediate

What is the most significant problem with concluding that a pharmaceutical batch failure was caused by “human error” without further analysis?

A) Human error is not an acceptable root cause under FDA regulations
B) Human error is a symptom or proximate cause, not a root cause — it describes what happened but not why the conditions existed that allowed the error
C) Human error conclusions always require a consent decree
D) Human error is only acceptable as a root cause if two analysts independently verify it

Question 8 | Advanced

During an OOS Phase 2 investigation, a raw material lot used in the failed batch is also identified in three other released batches. What must the manufacturer do?

A) No action is needed since the other batches have been released without complaints
B) Assess all three batches for the same failure mode, review their test results, and determine whether any corrective action including recall is warranted
C) Notify FDA only if one of the three batches has already reached patients
D) Place the three batches on hold but take no further action pending the Phase 2 conclusion

Section 4: Scenario-Based Questions

Question 9 | Advanced

An FDA 483 observation states: “Your firm’s OOS investigation system is deficient in that 70 percent of OOS investigations over the past 24 months were closed with ‘laboratory error, analyst retrained’ as the root cause with no documented Phase 1 analysis.” What does this most likely indicate?

A) The lab analysts need more training
B) The investigation system has a structural gap: it accepts “laboratory error” as a final root cause without requiring documented Phase 1 analysis of what the error was and why it occurred
C) The site has unusually poor laboratory technique compared to industry benchmarks
D) The site should replace its analysts

Question 10 | Advanced

A senior analyst retests a batch sample with an OOS microbiological result and obtains a passing result. The QA manager proposes to invalidate the original OOS and release the batch based on the senior analyst’s result. Is this acceptable?

A) Yes, because a senior analyst’s passing result overrides a junior analyst’s OOS result
B) No, because an OOS result can only be invalidated if a specific, documented, assignable laboratory cause is identified — not on the basis of a subsequent passing result alone
C) Yes, if the batch record is otherwise complete and satisfactory
D) Only acceptable if the senior analyst holds a PhD or equivalent qualification

Section 5: Advanced Scenarios

Question 11 | Advanced

A pharmaceutical quality unit finds that 35 percent of CAPAs closed in the past 12 months have recurred within that same period. What does this most likely indicate?

A) The site has unusually high random manufacturing variability
B) The root cause analysis step is producing conclusions that do not identify the true underlying cause, resulting in corrective actions that do not prevent recurrence
C) The CAPA effectiveness check process is working correctly by catching recurrences
D) The site needs to hire more QA staff to process CAPAs faster

Question 12 | Beginner

Under 21 CFR 211.22, what role must the Quality Control Unit (QCU) play in batch failure investigations?

A) The QCU is optional for investigation oversight if the production department has sufficient quality resources
B) The QCU must review and approve all production and control records before batch release, and has the authority and responsibility to approve or reject all decisions related to investigations
C) The QCU’s role is limited to signing the final investigation report
D) The QCU only becomes involved if the batch has been distributed

Question 13 | Intermediate

A stability study for a commercial pharmaceutical product shows an OOS result at the 18-month time point. What must the manufacturer do?

A) Discard the 18-month result and continue the study from the 24-month time point
B) Investigate the OOS result under 21 CFR 211.192, assess whether the product on the market meets its approved shelf life, and notify FDA if the data suggest the product may not meet its approved specifications
C) Extend the product’s expiry date to allow more time for the stability program to provide additional data
D) Retest the same sample and use the average of the original and retest results

Question 14 | Advanced

An FDA inspector asks a pharmaceutical manufacturer why an investigation was closed with “no root cause identified” after a Phase 2 investigation. What is the minimum the manufacturer must demonstrate to support this conclusion?

A) That the batch was eventually released and no complaints were received
B) That both Phase 1 and Phase 2 were conducted with documented methodology, all plausible causes were evaluated and ruled out with evidence, and the conclusion is supported by the data reviewed
C) That a senior quality manager approved the investigation closure
D) That the batch was retested and passed

Question 15 | Advanced

A pharmaceutical manufacturer’s investigation SOP requires all OOS investigations to be closed within 30 business days. The investigation of a complex contamination event is genuinely incomplete at 30 days. What should the QCU do?

A) Close the investigation at 30 days with the data available and document it as complete
B) Extend the investigation timeline with documented justification, ensure appropriate interim controls are in place, and complete the investigation to a scientifically sound conclusion
C) Release the batch at 30 days regardless of the investigation status
D) Transfer responsibility for the investigation to the production department to meet the deadline

Quick Reference: OOS Investigation Framework

The two-phase OOS framework under FDA guidance

Phase 1: Laboratory Investigation

Conducted by analyst and supervisor. Reviews: calculation errors, instrument calibration, standard preparation, sample preparation, analyst technique. Outcome: assignable cause found (OOS may be invalidated with documented evidence) or no assignable cause (proceed to Phase 2).

Phase 2: Manufacturing Investigation

Conducted when Phase 1 finds no assignable laboratory cause. Reviews: raw material lots, manufacturing process, equipment, environmental monitoring, operator records, deviations. Must extend to other batches per 21 CFR 211.192. Batch disposition decision follows conclusion.